Surgcenter is a service oriented business model based on patient visits and range of available procedures. Mesoblast is a product developer with no distribution. Surgcenter can’t help with clinical trials except perhaps to channel already identified candidates, which pushes what it can contribute a bit further along than just offering a product distribution channel. There lies the possible basis for a JV or some sort of alliance.
If the CLBP indication has the RMAT designation, it will benefit from having a large number of clinical trial sites if it is considered for an AA (cf FDA’s guidance on AA for RMAT designated products). Surgcenter can offer that.
Ann: Change in substantial holding, page-33
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.150(13.0%) |
Mkt cap ! $1.490B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.33 | $1.15 | $25.26M | 19.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 161000 | $1.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 50400 | 2 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |